5results about How to "Minimally invasive" patented technology

This application discloses a hydrogel composition, its preparation method, and its applications, relating to the fields of regenerative medicine and biomedical materials technology. The hydrogel composition comprises o-nitrobenzyl alcohol-modified tetra-arm polyethylene glycol and methacrylated hyaluronic acid. The hydrogel composition provided in this application addresses the problems in related technologies that rely on tissue flaps or prostheses for repair, such as large trauma, easy foreign body reaction, asymmetrical shape, unnatural feel, and the inability of tissue engineering materials to be rapidly molded intraoperatively, requiring secondary surgery.

The application discloses a plasma metabolic marker composition and a screening method and application thereof, and relates to the technical field of biomedicine. The plasma metabolic marker composition comprises glycyl-L-glutamic acid, phosphatidylcholine 38:7, pyrrole-2-formic acid and phosphatidylethanolamine 36:2p. The metabolic marker composition is significantly different in different cancer types, can distinguish different cancer types of cancer patients, and realizes the detection of pan-cancer. The metabolic marker composition is non-invasive and minimally invasive when used for the detection of pan-cancer, is more suitable for the screening and detection of a large number of ordinary people, has high sensitivity and specificity, is more suitable for the early screening of cancer, and is helpful for the early screening, early diagnosis and early treatment of cancer, and is helpful for improving the survival rate and cure rate of cancer patients.

This invention proposes a mitral valve capture mechanism for transcatheter interventional therapy, comprising: a capture unit, sleeved outside a control rod and located behind a clamping device, comprising: a base with an axially extending through-hole for the control rod to pass through, the front end of which is connected to a plurality of circumferentially distributed shape memory alloy units; a rigid unit, correspondingly arranged and connected to the shape memory alloy units, comprising an anterior rigid plate and a posterior rigid plate, wherein the anterior and posterior rigid plates do not contact each other, nor does the posterior rigid plate contact the base; a limiting ring, located in front of the shape memory alloy units and connected to the anterior rigid plate; a first cable control unit and a second cable control unit. This invention can effectively solve the problem of valve floating due to blood flow during mitral valve edge-to-edge repair, leading to clamping failure.

The invention provides a hydrogel composite microneedle as well as a preparation method and application thereof. The preparation method comprises the following steps: preparing a mixed solution from a sodium hydroxide solution and a phosphate solution; a uniform and transparent solution is obtained from the low-molecular sodium hyaluronate and the mixed solution; obtaining a first uniform solution from the uniform transparent solution, N, N-dimethylformamide and methacrylic anhydride; adjusting the pH value of the first uniform solution to obtain a second uniform solution; utilizing the second uniform solution to obtain a white flocculent solution; obtaining a white precipitate through the white flocculent solution; dissolving the white precipitate in ultrapure water, and dialyzing to obtain dialyzed liquid; performing vacuum freeze drying on the dialyzed liquid to obtain a MeHA solid; obtaining an M-G solution through the MeHA solid; and obtaining the hydrogel composite microneedle by using the M-G solution. According to the method, the sample extraction efficiency is improved through an extraction and detection two-step method, and stable signals can be kept in the detection process.

The application discloses application of exosome miRNA markers in evaluation of curative effect of immunotherapy combined with chemotherapy on small cell lung cancer patients. The exosome miRNA markers are a combination of miR-338-5p, miR-345-5p, miR-150-5p, miR-7706 and miR-328-3p. It is found for the first time that a combination of plasma exosome miRNA and TNM stage can be used as a marker to effectively predict a population benefiting from an immunotherapy combined with chemotherapy treatment scheme. Due to the unique structure of the exosome and the advantages of liquid biopsy technology, the exosome miR-338-5p, miR-345-5p, miR-150-5p, miR-7706, miR-328-3p and TNM stage combination of the application has high sensitivity and convenience as a population screening for benefiting from an immunotherapy combined with chemotherapy combined treatment scheme.